Background Current treatment guidelines recommend adjuvant mitotane after resection of
adrenocortical carcinoma with high-risk features (eg, tumor rupture, positive margins …

Background. The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always
been in controversy. We aimed to assess the prognostic benefits of adjuvant mitotane after …

Background Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of
recurrence after radical resection. Whether the use of mitotane is beneficial as an adjuvant …

Abstract Background: The ESE-ENSAT guidelines on the management of adrenocortical
carcinoma (ACC) suggest adjuvant mitotane for patients at high risk of recurrence following …

Objective Many patients with adrenocortical carcinoma (ACC) suffer from tumor recurrence
despite radical surgery. Evidence on the post-operative use of mitotane is controversial and …

Context: In 2007, a retrospective case-control study provided evidence that adjuvant
mitotane prolongs recurrence-free survival (RFS) in patients with radically resected …

Background. Adrenocortical carcinoma is a rare and aggressive disease with a poor
prognosis. Adjuvant mitotane administration has been suggested as a strategy that might …

Context Mitotane plasma concentrations≥ 14 mg/l have been shown to predict tumor
response and better survival in patients with advanced adrenocortical carcinoma (ACC). A …

Background A recent nonrandomized interinstitutional study reported that adjuvant mitotane
following surgery for adrenocortical carcinoma (ACC) was associated with decreased …

A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal
duration of adjuvant mitotane treatment. We tried to address this question, assessing …